Paricalcitol, USP, the active ingredient in Zemplar Capsules, is a synthetically manufactured, metabolically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 microgram, 2 micrograms or 4 micrograms of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene. The medium chain triglycerides are fractionated from coconut oil or palm kernel oil. The capsule shell is composed of gelatin, glycerin, titanium dioxide, iron oxide red (2 microgram capsules only), iron oxide yellow (2 microgram and 4 microgram capsules), iron oxide black (1 microgram capsules only), and water.
Chronic Kidney Disease Stages 3 and 4
Zemplar Capsules are indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4.
Chronic Kidney Disease Stage 5
Zemplar Capsules are indicated for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).
Media Articles Related to Zemplar (Paricalcitol)
Rayaldee Approved by FDA for Secondary Hyperparathyroidism
Source: Medscape Nephrology Headlines [2016.06.21]
The FDA has approved calcifediol (Rayaldee, Opko Health, Inc) for the treatment of adults with secondary hyperparathyroidism associated with vitamin D insufficiency in stage 3 to 4 CKD.
Published Studies Related to Zemplar (Paricalcitol)
Effect of paricalcitol on circulating parathyroid hormone in X-linked
hypophosphatemia: a randomized, double-blind, placebo-controlled study. 
patients... CONCLUSIONS: Suppression of PTH may be a useful strategy for skeletal improvement
Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. [2011.08.30]
BACKGROUND: The efficacy of 25-hydroxyvitamin D (25[OH]D) supplementation versus vitamin D receptor activators for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) stages 3 or 4 and vitamin D deficiency is unclear... CONCLUSIONS: Paricalcitol is more effective than ergocalciferol at decreasing PTH levels in patients with CKD stages 3 or 4 with vitamin D deficiency and SHPT. Published by Elsevier Inc.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. [2010.11.06]
BACKGROUND: Despite treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors, patients with diabetes have increased risk of progressive renal failure that correlates with albuminuria. We aimed to assess whether paricalcitol could be used to reduce albuminuria in patients with diabetic nephropathy... INTERPRETATION: Addition of 2 mug/day paricalcitol to RAAS inhibition safely lowers residual albuminuria in patients with diabetic nephropathy, and could be a novel approach to lower residual renal risk in diabetes. FUNDING: Abbott.
Effect of paricalcitol on the urinary peptidome of kidney transplant patients. [2010.10]
BACKGROUND AND OBJECTIVE: Disorders in bone mineral metabolism are common after kidney transplantation, covering, among other pathologic conditions, secondary hyperparathyroidism. Paricalcitol, a selective vitamin D receptor activator, is indicated in the prevention and treatment of secondary hyperparathyroidism. Recent evidence suggests that paricalcitol is also associated, by mechanisms not yet clarified, with improved patient survival. To clarify these unknown mechanisms, the aim of this study was to determine whether 3 months of treatment with paricalcitol modified the urinary peptidome of kidney transplant patients... CONCLUSIONS: With this preliminary study, we obtained a profile of urinary peptides in which changes occurred due to treatment with paricalcitol. The identification of proteins to which these peptides belong may improve our knowledge about the possible pleiotropic effects of paricalcitol. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. 
BACKGROUND/AIMS: Increased parathyroid activity associated with chronic kidney disease is often managed with calcitriol, which can elevate serum calcium (Ca) by increasing bone resorption and intestinal absorption, whereas paricalcitol promotes less bone resorption. This study compared intestinal Ca absorption in hemodialysis patients treated with calcitriol versus paricalcitol (dose ratio 1:3)... CONCLUSION: Overall, paricalcitol-treated patients absorbed approximately 14% less Ca compared with calcitriol-treated patients with similar effects on PTH. In hemodialysis patients, paricalcitol may provide a benefit by lowering the Ca available for removal by dialysis and/or for deposit in bone or soft tissues. Copyright (c) 2009 S. Karger AG, Basel.
Clinical Trials Related to Zemplar (Paricalcitol)
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis [Completed]
Prospective, non-randomized, multi-center study to assess the efficacy and safety of
paricalcitol injection or oral administered over 6 months to patients with secondary
hyperparathyroidism on dialysis.
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors [Completed]
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of
paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease
(CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting
enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) therapy.
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D [Completed]
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin
Oral Paricalcitol in Kidney Transplant Recipients [Completed]
This study is being done to find out whether patients who receive a kidney transplant can
benefit from taking the medication paricalcitol (trade name Zemplar«) as compared to kidney
transplant recipients not taking this medication. The main possible benefits being studied
- Lower risk for overactive parathyroid glands after kidney transplantation.
- Lower risk of low bone density in the spine and hip after kidney transplantation. By
dividing patients in the study into a group receiving Zemplar« and a group not
receiving Zemplar«, it will be possible to understand the good and bad effects of
Zemplar┬« during the first year after a kidney transplant.
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation [Completed]
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation,
blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become
abnormally stimulated and accumulate in the kidney and cause damage to the kidney. The
purpose of this study is to determine if paricalcitol helps improve kidney injury, blood
pressure control and kidney function in patients with chronic kidney disease. The study will
last about 7 weeks and involves about 8 visits to the medical center.
Reports of Suspected Zemplar (Paricalcitol) Side Effects
Cardiac Failure (16),
Renal Failure Chronic (15),
Myocardial Infarction (14),
Cardiac Arrest (13), more >>
Page last updated: 2016-06-21